The FIGHT-101 trial became the cornerstone for the FIGHT-202 trial, which enrolled patients with CCA harbouring FGFR2 gene fusions or rearrangements, other FGFR aberrations, or without FGFR aberrations (NCT02924376) [8]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.